Detalhe da pesquisa
1.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma.
Blood
; 143(7): 592-596, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048557
2.
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Blood
; 137(22): 3027-3036, 2021 06 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739404
3.
High levels of hypusinated eIF5A in leiomyoma and leiomyosarcoma pathologies: a possible novel therapeutic target.
Reprod Biomed Online
; 47(1): 15-25, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37137790
4.
Control of the eIF4E activity: structural insights and pharmacological implications.
Cell Mol Life Sci
; 78(21-22): 6869-6885, 2021 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-34541613
5.
Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Int J Mol Sci
; 23(24)2022 Dec 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36555520
6.
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Lancet Oncol
; 22(12): 1705-1720, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34774221
7.
European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Haematologica
; 106(8): 2054-2065, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792221
8.
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma.
Ann Hematol
; 100(2): 437-443, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33392702
9.
Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.
Haematologica
; 105(7): 1937-1947, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31582542
10.
Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True.
Int J Mol Sci
; 21(21)2020 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139668
11.
Update and European consensus on a patient-centered core outcome set for multiple myeloma in clinical practice and research.
Haematologica
; 109(6): 1956-1959, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299690
12.
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies.
Am Soc Clin Oncol Educ Book
; 44(3): e433520, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38772002
13.
Crystal structure of archaeal IF5A-DHS complex reveals insights into the hypusination mechanism.
Structure
; 2024 Mar 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582076
14.
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells.
Blood Cancer J
; 14(1): 94, 2024 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38849344
15.
Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients.
Br J Haematol
; 182(2): 165-167, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29732537
16.
Multi-fuel driven Janus micromotors.
Small
; 9(3): 467-71, 2013 Feb 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-23055445
17.
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop.
Clin Lymphoma Myeloma Leuk
; 23(6): 413-419, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37055346
18.
Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma.
medRxiv
; 2023 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38106151
19.
Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Exp Hematol Oncol
; 12(1): 71, 2023 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37563685
20.
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing.
EClinicalMedicine
; 60: 102016, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37396800